EVALUATE THE TOLERABILITY OF RIFAXIMIN IN PREVENTING HEPATIC ENCEPHALOPATHY (HE)

这个子项目是众多研究子项目之一

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Compare the maintenance of remission from previously demonstrated HE as measured by Conn score and asterixis grade during 6 months of treatment with rifaximin at 550 mg BID or placebo.